- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Digital osteoarthritis, bulimia tools backed for NHS use | ||
| Fr | Sanofi plans amlitelimab dermatitis filing after new readout | ||
| Fr | Corxel's raises $287m for obesity drug, and other financings | ||
| Fr | Change of heart as NICE backs prostate cancer drug Talzenna | ||
| Fr | Ovarian cancer data restores faith in Corcept's relacorilant | ||
| Do | J&J says 2026 sales could top $100 billion | ||
| Do | Amazon joins the AI health assistant movement | ||
| Do | NICE backs Roche lupus drug that supports kidney function | ||
| Do | US checks out of WHO, leaving its bill unsettled | ||
| Do | 11 high-impact drugs to look out for in 2026 | ||
| Mi | EU approves Otsuka's long-acting HAE drug Dawnzera | ||
| Mi | Hopstem maps course to bring stem cell stroke therapy to US | ||
| Mi | ImmunityBio rises as route opens to broader Anktiva label | ||
| Mi | Call goes out for type 1 diabetes screening in UK | ||
| Mi | Data builds behind Moderna's skin cancer vaccine | ||
| Di | J&J bets on Isomorphic for AI-powered drug hunt | ||
| Di | ViiV ownership shifts as Pfizer sells its stake | ||
| Di | Agomab and Spyglass push the IPO button | ||
| Di | AstraZeneca pays $630m to get full control of AbelZeta CAR-T | ||
| Di | GSK reaches $2.2bn deal to buy food allergy biotech RAPT | ||
| Mo | Sun Pharma says talk of $10bn Organon bid is 'speculative' | ||
| Mo | EU starts review of first-line Enhertu for breast cancer | ||
| Mo | Could Alzheimer's be predicted with a finger-prick test? | ||
| Mo | NICE relents, ending postcode access to prostate cancer drug | ||
| Mo | 'Skinny' generic Vascepa label case reaches US Supreme Court |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.